Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
PsyMed Ventures is a venture capital fund founded in 2020 and headquartered in San Francisco, California. The firm focuses on investing in the future of brain and mental health through innovative neuroscience and frontier technologies. With a fund size of $25 million, PsyMed Ventures has built a portfolio of 17 companies, emphasizing advancements in mental health and neurological disorders.
The firm was established by Dina Burkitbayeva, Greg Kubin, and Matias Serebrinsky, who share a vision of transforming mental health care through impactful solutions. PsyMed Ventures has a strong commitment to addressing mental health disorders and neurological diseases, aiming to support groundbreaking advancements in areas such as neurotechnology, digital health, and psychedelic medicine.
Since its inception, PsyMed Ventures has focused on creating a new era of personalized and effective treatments for mental health challenges. The firm actively engages with its portfolio companies, providing strategic guidance and operational support to help them navigate the complexities of the mental health landscape.
PsyMed Ventures invests in a variety of sectors related to brain and mental health, including healthcare, biotech, AI, digital health, and fintech. The firm targets companies at the Pre Seed, Seed, Seed Plus, Series A, and Series A Plus stages, with check sizes ranging from $500,000 to $1,500,000. Their investment strategy emphasizes innovative neuroscience and frontier technologies aimed at addressing mental and brain health issues.
Key areas of focus include neurotechnology, digital health solutions, precision neuroscience, psychedelic medicine, and alternative modalities. PsyMed Ventures seeks to partner with companies that leverage these innovative approaches to create impactful solutions for mental health challenges. The firm is particularly interested in supporting advancements in psychedelic medicine and alternative therapies, which are gaining traction in the mental health sector.
In their own words, PsyMed Ventures aims to transform the mental and brain illness epidemic into a flourishing future through their investments. They look for founders who align healing, responsibility, and profitability in the mental health sector, ensuring that their portfolio companies are well-positioned to make a significant impact.
PsyMed Ventures has invested in a diverse range of companies that are making strides in mental health and neuroscience. Notable portfolio companies include:
This portfolio reflects PsyMed Ventures' commitment to investing in companies that are pioneering advancements in mental health technologies and treatments.
Dina Burkitbayeva: Co-founder and General Partner at PsyMed Ventures. She has a background in neuroscience and has co-founded portfolio company Freedom Biosciences, focusing on ketamine and psychedelic therapeutics. Burkitbayeva has extensive experience in the mental health sector and is known for her operational expertise.
Greg Kubin: Co-founder and General Partner at PsyMed Ventures. Kubin has a strong background in venture capital and has been involved in various successful investments in the healthcare sector. His expertise lies in identifying promising startups and guiding them through the early stages of growth.
Matias Serebrinsky: Co-founder and General Partner at PsyMed Ventures. Serebrinsky brings a wealth of experience in the biotech industry, with a focus on innovative drug development. He has a track record of leading investments in companies that are pioneering advancements in mental health technologies.
To pitch PsyMed Ventures, founders should submit their proposals through the firm's website at psymed.ventures. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Founders are encouraged to highlight how their innovations align with PsyMed's focus on mental health technologies.
While there is no specific application form, a well-structured deck that addresses key investment criteria will enhance the chances of receiving a timely response. PsyMed Ventures appreciates warm introductions, but cold pitches are also welcome. Founders should expect a response within a few weeks, depending on the volume of submissions.
In November 2024, PsyMed Ventures made a notable investment in Jimini Health, a pre-seed company focused on AI-assisted therapy tools for therapists. This investment aligns with the firm's commitment to advancing mental health technologies.
Throughout 2024, PsyMed Ventures has actively deployed capital into transformative mental health technologies, with a portfolio that includes companies like Aerska, Alto Neuroscience, and ATAI Life Sciences. The firm has made seven investments specifically in the psychedelics and neurotechnology sectors, demonstrating its focus on innovative approaches to mental health challenges.
What are PsyMed Ventures' investment criteria?
PsyMed Ventures focuses on investing in companies that are innovating in the fields of brain and mental health. They target sectors such as neurotechnology, digital health, precision neuroscience, psychedelic medicine, and alternative modalities. The firm invests at various stages, including Pre Seed, Seed, Seed Plus, Series A, and Series A Plus, with check sizes ranging from $500,000 to $1,500,000.
How can founders apply or pitch to PsyMed Ventures?
Founders interested in pitching to PsyMed Ventures can submit their proposals through the firm's website at psymed.ventures. It is recommended to include a detailed business plan, information about the team, and how the company aligns with PsyMed's focus on mental health innovations.
What makes PsyMed Ventures different from other venture capital firms?
PsyMed Ventures distinguishes itself by concentrating specifically on brain and mental health technologies. The firm has a deep understanding of the neuroscience field and provides strategic guidance and operational support to its portfolio companies. Their focus on psychedelic medicine and alternative therapies sets them apart in the venture capital landscape.
What is PsyMed Ventures' geographic scope?
The firm primarily invests in companies based in the United States. They are particularly interested in startups that are developing innovative solutions to address mental health challenges within the country.
What kind of post-investment involvement does PsyMed Ventures have?
PsyMed Ventures actively engages with its portfolio companies, offering strategic guidance and operational support. The team leverages their industry expertise and network to help companies navigate the complexities of the mental health landscape and accelerate their growth.
What is the fund size and check size range for PsyMed Ventures?
PsyMed Ventures has a fund size of $25 million and typically invests between $500,000 and $1,500,000 in each portfolio company. This allows them to support early-stage companies with the necessary capital to develop their innovative solutions.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.